By Tom Winnifrith | Saturday 2 October 2021
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Life sciences compounds developer OptiBiotix Health (OPTI) has announced results for the first of calendar 2021, emphasising “sales of LPLDL and SlimBiome of £1.076m, a 44.5% increase over H1:2020… pleasing given the continued uncertain global economic environment and challenges of the subsequent waves of COVID-19, particularly in countries like India and the USA”. The shares have currently responded slightly higher, to 50p.